



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

- (15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see page(s) 9-11
- (48) Corrigendum issued on:
02.10.2002 Bulletin 2002/40
- (45) Date of publication and mention
of the grant of the patent:
27.03.2002 Bulletin 2002/13
- (21) Application number: **99919282.6**
- (22) Date of filing: **13.05.1999**
- (51) Int Cl.7: **A61K 38/21**
- (86) International application number:
PCT/ES99/00134
- (87) International publication number:
WO 99/058143 (18.11.1999 Gazette 1999/46)

(54) **UTILIZATION OF INTERFERON ALPHA 5 IN THE TREATMENT OF VIRAL HEPATOPATHIES**

VERWENDUNG VON INTERFERON ALPHA 5 IN DER BEHANDLUNG VIRALER HEPATOPATHIEN
UTILISATION DE L'INTERFERON ALPHA 5 DANS LE TRAITEMENT DES HEPATOPATHIES
VIRALES

- | | |
|--|--|
| <p>(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI</p> <p>(30) Priority: 13.05.1998 ES 9801003</p> <p>(43) Date of publication of application:
21.02.2001 Bulletin 2001/08</p> <p>(73) Proprietor: Fundacion para la Investigacion
Medica Aplicada
31008 Pamplona (ES)</p> <p>(72) Inventors:
 <ul style="list-style-type: none"> • PRIETO VALTUENA, Jesús
E-31002 Pamplona (ES) • CIVEIRA MURILLO, M Pilar
E-31008 Pamplona (ES) • LARREA LEOZ, Esther
E-31008 Pamplona (ES) </p> <p>(74) Representative: Elzaburu, Alberto de et al
Elzaburu S.A.
Miguel Angel, 21
28010 Madrid (ES)</p> <p>(56) References cited:</p> | <ul style="list-style-type: none"> • JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, FOSTER G.R. ET AL: 'Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency' vol. 16, no. 12, 1996, pages 1027 - 1033 • THE NEW ENGLAND JOURNAL OF MEDICINE, DAVIS G.L. ET AL: 'Treatment of chronic hepatitis C with recombinant interferon alfa' vol. 321, no. 22, 1989, pages 1501 - 1506 • CLINICAL INFECTIOUS DISEASES, SORIANO V. ET AL: 'Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus' vol. 23, 1996, pages 585 - 591 • INFECTION, MAUSS S. ET AL: 'Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4 + cell count' vol. 26, no. 1, 1998, pages 16 - 19 • JOURNAL OF INFECTION, SORIANO V. ET AL: 'Efficacy and safety of alpha-interferon treatment for chronic hepatitis C in HIV - infected patients' vol. 31, 1995, pages 9 - 13 • THE NEW ENGLAND JOURNAL OF MEDICINE, DI BISCEGLIE A. ET AL: 'Recombinant interferon alpha therapy for chronic hepatitis C' vol. 321, 1989, pages 1506 - 1510 |
|--|--|

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

Scope of the invention

5 [0001] The invention relates to the production of interferon alpha 5 for use in compositions useful in the treatment of liver diseases of viral origin.

[0002] We have shown that IFN-alpha 5 is the sole subtype of alpha interferon produced in the healthy liver and that its levels are clearly reduced in chronic hepatitis C, which suggests that this substance may be of therapeutic value in the treatment of this disease and other forms of viral hepatitis. Knowing the coding gene sequence for this interferon, its production through recombinant DNA technology in different hosts makes it possible to develop effective drugs for the treatment of liver diseases of this type at their different stages of development.

10 [0003] The invention is defined in claims 1-9.

State of the art

15 [0004] Infected cells can recognize the presence of a virus by sending out signals which result in the transcription and secretion of type I interferon (IFN α and IFN β). IFN α is a family of thirteen polypeptides (subtypes) coded by different genes. IFN β is a glycoprotein produced by a single gene. Different cell types produce both IFN α and IFN β (1, 2).

[0005] Viral infection is the main stimulus for the production of type I interferon, although there are other factors which can increase its synthesis, such as bacterial components, double chain RNA, growth factors and other cytokines (1). In addition to having its antiviral effect, IFN α can interact with certain cytokines and with T cells regulating the growth and differentiation of the cells in the immune system (3). IFN α genes are expressed as a matter of course in human tissue in healthy individuals (4), while the expression of particular subtypes is restricted to certain cell types (5, 6). The induction of IFN by viruses is mainly regulated at transcription level. The specific activation of transcription occurs through the interaction of cell factors induced by viruses with the domains regulating the promoters of IFN α genes (7).

20 [0006] All IFN α and IFN β subtypes have a common receptor at the cell surface. Competitive binding tests at the receptor for different IFN α subtypes indicate that all of these combine at the same receptor, but with different affinities (8). The biological activity of the different subtypes of IFN α is little known. The IFN α 5 and IFN β 8 interferon subtypes appear to be those having the greatest antiviral activity. Antiproliferative response also differs between the different subtypes (9). In humans unstimulated peripheral blood mononuclear cells express different IFN α subtypes (10).

[0007] A common mechanism for the persistence of viral infection is avoidance of the IFN system. Many viruses have developed strategies to avoid the antiviral effects of IFN. Specifically, a selective defect in the production of IFN α has been described in monocytes infected by human immunodeficiency virus (11).

35 Hepatitis C virus (HCV) is a single chain RNA virus which results in chronic infection in more than two thirds of persons infected. The prevalence of infection by HCV is around 2 to 3% in the population of the West. Studies performed in Europe show that 33% of patients with chronic HCV infection develop cirrhosis in a mean period of less than 20 years (12). A significant proportion of these patients develop liver cancer, with an annual incidence of 1.4% (13). It has been difficult to find the reason for the high level of persistence of HCV infection. The high rate of mutations in the virus and the production of a predominant profile of Th2 cytokines in comparison with Th1 have been described as being responsible for this high level of persistence by the infection. Treatment with IFN induces a sustained response in around 30% of patients with chronic hepatitis C. The mechanism responsible for response or non-response to treatment with IFN is little understood.

40 [0008] The IFN system has only been studied in chronic HCV infection. There is no appropriate animal model for chronic HCV infection, and, because of this, investigations performed on humans are the only source of information on the pathophysiology and pathogenesis of chronic hepatitis C. This invention describes the expression of IFN α and IFN β genes in the liver and in the peripheral blood mononuclear cells (PBMC) in healthy controls and patients with chronic hepatitis C. In addition to this we have analysed the IFN α subtype expressed in normal liver tissue and the liver tissue of patients with chronic hepatitis C. Expression of the different IFN α subtypes has also been analysed in PBMC in healthy controls and patients with chronic hepatitis C.

REFERENCES

[0009]

55 1. Maeyer E, Maeyer-Guignard J. Interferons. In Thomson A, ed. The Cytokine Handbook. London: Academic Press Limited 1991: 215-239.

EP 1 077 068 B9 (W1B1)

2. Samuel CE. Antiviral Actions of Interferon. Interferon-Regulated Cellular Proteins and Their Surprisingly Selective Antiviral Activities. *Virology* 1991; 183: 1-11.

5 3. Tilg H. New Insights Into the Mechanisms of Interferon Alfa: An Immunoregulatory and Anti-inflammatory Cytokine. *Gastroenterology* 1997; 112: 1017-1021.

10 4. Tovey MG, Streuli M, Gresser I, Gugenheim I, Blanchard B, Guymarho J, Vignaux F and Gigou M. Interferon messenger RNA is produced constitutively in the organs of normal individuals. *Proc. Natl. Acad. Sci. USA* 1987; 84: 5038-5042.

15 5. Bisat F, Raj NB, Pitha PM. Differential and cell type specific expression of murine alpha interferon genes is regulated on the transcriptional level. *Nucleic Acids Res* 1988; 16:6067-6083.

20 6. Hiscott J, Cantell K, Weissmann C. Differential expression of human interferon genes. *Nucleic Acids Res* 1984; 12:3727-3746.

25 7. Au WC, Su Y, Raj NBK and Pitha PM. Virus-mediated Induction of Interferon A Gene Requires Cooperation between Multiple Binding Factors in the Interferon α Promoter Region. *The Journal of Biological Chemistry* 1993, 268: 24032-24040.

30 8. Aguet M, Grobke M, Dreiding P. Various human interferon alpha subclasses cross-react with common receptors: their binding affinities correlate with their specific biological activities. *Virology* 1984;132:211-216.

35 9. Foster GR, Rodrigues O, Ghouze F, Schulte-Frohlinde D, Testa D, Liao MJ, Stark GR, Leadbeater L, Thomas HC. Different relative activities of human cell derived interferon-alpha subtypes: interferon alpha 8 has very high antiviral potency. *J Interferon and Cytokine Res.* 1996; 16:1027-1033.

40 10. Brandt ER, Linnane AW, Devenish RJ. Expression of IFN A genes in subpopulations of peripheral blood cells. *Br J Haematol* 1994; 86:717-725.

45 11. Gendelman HE, Friedman RM, Joe S, Baca LM, Turpin JA, Dveksker G, Meltzer MS and Dieffenbach C. A Selective Defect of Interferon α Production in Human Immunodeficiency Virus-infected Monocytes. *The Journal of Experimental Medicine* 1990; 172: 1433-1442.

50 12. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. *Lancet* 1997; 349:825-832.

55 13. Fattovich G, Giustina G, Degos F et al. Morbidity and Mortality in Compensated Cirrhosis Type C: A Retrospective Follow-Up Study of 384 Patients. *Gastroenterology* 1997;112: 463-472.

14. Gil B, Qian Ch, Riezu-Boj JI, Civeira MP, Prieto J. Hepatic and extrahepatic HCV RNA strands in chronic hepatitis C: different patterns of response to interferon treatment. *Hepatology* 1993;18:1050-1054.

15. Lopez S, Reeves R, Island ML, Bandu MT, Christeff N, Doly J and Navarro S. Silencer Activity in the Interferon-A Gene Promoters. *The Journal of Biological Chemistry* 1997; 272: 22788-22799.

16. Knodell R, Ishak K, Black W, Chen T, Craig R, Kaplowitz N, Kiernan T, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. *Hepatology* 1981; 1:431-435.

17. Chomczynsky P; Sacchi N. Single-step of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.* 1987; 162:156-159.

18. Weissmann C, Weber H. The interferon genes. *Prog Nucleic Acid Res Mol Biol* 1986; 33:251-300.

19. Goeddel DV, Leung DW, Dull TJ, Gross M, Lawn RM., McCandliss R, Seeburg PH, Ullrich A, Yelverton E, Gray PW. The structure of eight distinct cloned human leukocyte interferon cDNAs. *Nature* 1981; 290:20-26.

20. Derynck R, Content J, DeClercq E, Volckaert G, Tavernier J, Devos R, Fiers W. Isolation and structure of a human fibroblast interferon gene. *Nature* 1980; 285:542-547.

21. Ng SY, Gunning P, Eddy R, Ponte P, Leavitt J, Shows T, Kedes L. Evolution of the functional human b-actin gene and its multi-pseudogene family: conservation of noncoding regions and chromosomal dispersion of pseudogenes. *Mol Cell Biol* 1985; 5:2720-2732.

22. Larrea E, Garcia N, Qian Ch, et al. Tumor Necrosis Factor α Gene Expression And The Response To Interferon In Chronic Hepatitis C. *Hepatology* 1996; 23: 210-217.

23. Viazov S, Zibert A, Ramakrishnan K; Widell A; Cavicchini A, Schreier E; Roggendord M. Typing of hepatitis C virus isolates by DNA enzyme immunoassay. *J. Virol. Methods* 1994;48:81-92.

24. Sarobe P, Jauregui JI, Lasarte JJ, García N, Civeira MP, Borrás-Cuesta F and Prieto J. Production of interleukin-2 in response to synthetic peptides from hepatitis C virus E1 protein in patients with chronic hepatitis C: relationship with the response to interferon treatment. *J Hepatol* 1996;25:1-9.

DESCRIPTION OF THE INVENTION

Patients and controls

[0010] The expression of IFN α and IFN β genes was analysed in samples from liver biopsies from 16 patients with chronic hepatitis C (9 men and 7 women, age range 24 to 71 years). Five of these patients showed cirrhosis. The viral genotype was determined in 14 patients and was 1b in 10 patients, 1a in 2 patients and genotype 3 in 1 patient.

[0011] In addition to this, expression of the IFN α and IFN β genes was determined in 12 samples of normal liver obtained by laparotomy from 12 control patients (9 men and 3 women, age range 49 to 70 years). The laparotomies were performed on account of the presence of digestive tumours in 10 patients (4 colo-rectal, 5 gastric and 1 pancreatic) due to chronic pancreatitis in 1 patient and the presence of a hydatid cyst in another patient. Liver histology was normal in the twelve cases. None of these control cases had received treatment before the liver sample was obtained.

[0012] mRNA levels of IFN α and IFN β were also determined in PBMC in 25 patients with chronic hepatitis C (14 men and 11 women, age range 24 to 69 years) (four of these patients had cirrhosis) and in PBMC from 23 healthy controls (10 men and 13 women, age range from 25 to 66 years). The viral genotype for these patients was 1b in 22 patients, 1a in two patients and 3 in 1 patient.

[0013] The diagnosis of chronic hepatitis C was based on an increase in serum transaminases lasting more than 6 months, a positive result for anti-HCV antibodies (2nd generation ELISA, Ortho Diagnostic System, Raritan, NJ, USA), the presence of C virus RNA in serum (reverse-reaction transcription in the polymerase chain), and histological evidence of chronic hepatitis. The severity of liver damage was evaluated using the Knodell index (16). Other causes of chronic hepatitis other than hepatitis C virus were ruled out. None of the patients had received treatment with IFN α during at least 6 months prior to the study.

Preparation of liver, PBMC and serum samples

[0014] The liver samples were obtained by liver biopsy using a Tru-Cut biopsy needle (Baxter, Deerfield, IL). One third of the sample was immediately frozen in liquid nitrogen and kept at -80°C until total RNA extraction took place. The remainder of the sample was used for the histological investigation.

[0015] PBMC were isolated from heparinized blood using a density gradient with Lymphoprep (Nycomed Pharma As, Oslo, Norway), centrifuged at 600 g for 30 minutes. After centrifuging the PBMC were collected, washed 5 times with 0.9% NaCl and lysed using Ultraspec™ protein denaturing solution (Biotech Laboratories, Houston, USA). The cellular lysate was kept at -80°C until total RNA extraction was performed using the method of Chomczynski and Sacchi (17).

[0016] The serum samples were obtained by centrifuging from venous blood collected in sterile tubes. The serum was kept at -40°C until use.

Analysis of the expression of IFN α and IFN β genes in the liver and PBMC

[0017] mRNA levels of IFN α and IFN β were determined using a quantitative polymerase chain reaction reverse transcription (RT-PCR) method using a thermocycler (Perkin-Elmer Gene Amp PCR system 2400). Prior to reverse transcription 2 μ g of total RNA (from both the liver and PBMC) were treated with 1 unit of deoxyribonuclease (DNase

I amplification grade, Gibco-BRL, Gaithersburg, MD, USA) to eliminate possible contaminating DNA. The presence of traces of DNA was checked by including control reactions without reverse transcription. This step is required because of the absence of introns in IFN α and IFN β genes (18), which made it impossible for us to distinguish the product of PCR from the RNA or possible contaminating DNA. All the controls performed without reverse transcription were negative, indicating the absence of contaminating DNA. Total RNA was transcribed (60 minutes at 37°C) with 400 units of M-MuLV reverse transcriptase (Gibco- BRL, Gaithersburg, MD, USA) in a final volume of 40 μ l of 5 x saline solution (250 mM Tris-HCl pH 8.3, 375 mM KCl, 15 mM MgCl₂), supplemented with 5 mM DTT, 0.5 mM triphosphate deoxyribonucleotides (Boehringer Mannheim, Mannheim, Germany), 48 units of RNAsas inhibitor (Promega Corporation, MD, US) and 400 ng of random hexamers (Boehringer Mannheim, Mannheim, Germany). After denaturing the reverse transcriptase (95°C, 1 minute) and rapidly cooling over ice, a 10 μ l aliquot (0.5 μ g) of the cDNA was used to amplify the IFN α and IFN β by PCR in 50 μ l of 10 x PCR buffer (160 mM (NH₄)SO₄, 670 mM Tris-HCl pH 8.8, 0.1% Tween 20) supplemented with the direction and antidirection primers (40 ng of each one for IFN α and 60 ng for IFN β), 1.2 mM MgCl₂ and 2 units of Biotaq™ DNA polymerase (Biolone, London, LTK). Control reactions without RNA were performed in all the experiments. As an internal control for each sample a fragment of β -actin cDNA was amplified using a 10 μ l aliquot of the cDNA obtained previously. The IFN α was amplified by performing 30 or 33 cycles (PBMC or liver respectively) (94°C, 60°C and 72°C during 20, 15 and 30 seconds for each step respectively), the INF β was amplified by performing 30 or 35 cycles (PBMC or liver respectively) (94°C, 58°C and 72°C for 20, 15 and 30 seconds for each step respectively) and β -actin was amplified by reacting 18 or 25 cycles (PBMC or liver respectively) (94°C, 55°C and 72°C for 20, 15 and 30 seconds for each step respectively), protocols which avoid interference with the PCR reaction saturation stage. The oligonucleotides (5'-3') d(TCCATGAGATGATCCAGCAG) and d(ATTCTGCTCTGACAACCTCC) were used as direction and antidirection primers respectively to amplify a fragment of 274 pairs of bases located between nucleotides 240-514 in the human IFN α gene (19). These oligonucleotides are direction primers designed to amplify all the subtypes of IFN α . The oligonucleotides d(TCTAGCACTGGCTGGAATGAG) and d(GTTTCGGAGGTAACCTGTAAG) were the primers used to amplify a fragment of 276 base pairs located between nucleotides 349-625 of cDNA of human IFN β (20). d(TCTACAATGAGCTGCGTGTG) and d(GGTGAGGATCTTCATGAGGT) were the primers used to amplify a fragment of 314 base pairs (nucleotides 1319-2079) of the β -actin gene (21).

[0018] After the amplification reactions 20 μ l of the PCR product were run in a 2% agarose gel containing ethidium bromide. The bands obtained were displayed using an ultraviolet lamp and were analysed using a commercial programme (Molecular Analyst/PC, Bio-Rad) capable of digitizing and analysing the image obtained. Finally the values corresponding to the expression of the IFN α and IFN β genes were standardized with their β -actin correlates. The results are expressed as the quotient between the value of IFN α and IFN β and the β -actin correlate. Previously we demonstrated that the mRNA of β -actin was expressed constantly both in the liver and in the PBMC of patients with chronic hepatitis C (22), which has enabled us to standardize IFN α and IFN β values with those obtained for β -actin.

[0019] Validation curves for the PCR technique were prepared using known quantities of total RNA (from 0 up to 1 μ g). As will be seen in Figure 3, with the total initial RNA quantities used for IFN α , IFN β and β -actin (0.5 μ g, for both the liver and PBMC), we were within the linear range of the PCR amplification curve. The inter-test coefficient of variance for IFN α / β -actin was 22% and for IFN β / β -actin it was 24%. The identity of the PCR product obtained was checked for IFN α and IFN β by automatic sequencing (ABI prism™ 310 genetic analyser, Perkin Elmer).

Identification of IFN α subtypes

[0020] Total RNA extraction, reverse transcription and the PCR reaction were performed as described above, using the IFN α direction primers mentioned. The PCR product obtained was cloned using the commercial TOPO TA cloning kit (Invitrogen, Leek, Holland). At least 6 clones from each insert were sequenced in an automatic ABI PRISM 310 sequencer (Perkin Elmer, Foster, CA), using the Dye Rhodamine Terminator Cycle Sequencing Kit (Perkin Elmer, Foster, CA).

Detection, quantification and genotyping of C virus RNA

[0021] The presence of C virus RNA in serum was determined using the RT-PCR technique (14, 22), using 2 pairs of specific primers for the non-coding 5' region of the C virus genome. The C virus RNA was quantified using the competitive PCR technique previously described by ourselves (22). The viral genotype was determined using Viarov's method (23) as already described previously (22, 24). The test 5'G(A,G)CCGTCTTGGGGCC(A,C)AAATGAT was used to determine genotype 4.

Statistical analysis

[0022] The IFN α and IFN β results are presented as mean \pm standard error. The normality of the variables was studied

using the Shapiro-Wilks test. Statistical analysis of IFN α and IFN β values in PBMC or liver was performed using non-parametric tests (Mann-Whitney U test) or parametric tests (Student's T). The association between quantitative variables was investigated using the Pearson or Spearman correlation coefficient, as appropriate. Windows SPSS 6.0 program was used for the statistical analysis.

5

Production of recombinant protein

Expression and purification of human interferon- α 5 in *Escherichia coli*:

10 [0023] Despite the fact that the expression of cDNAs originating from eucaryote organisms in *Escherichia coli* in general ensures a high level of production, isolation and purification of the protein of interest involves complex procedures and low yields. For this reason expression vectors are used to help obtain merged proteins whose purification is reduced to an affinity chromatography step, with high yield and efficiency.

15 Construction of the expression vector and acquisition of recombinant bacteria

[0024] The cDNA which codes for interferon- α 5 is cloned in pET14b vector (available commercially from Novagen). This vector provides a sequence which codes for a series of histidine residues (1 kDa) which are translated in phase with the cloned cDNA to yield a merged protein which includes a 1 kDa histidine tail at its terminal amine end and then interferon- α 5, with a site between the two which can be cut by thrombin.

20 [0025] Once the expression vector has been obtained, competent bacteria of the BL21 (DE3) strain are prepared, as this strain contains a gene which can be induced by T7 RNA polymerase, which is a necessary requirement for the subsequent production of protein. The competent bacteria are converted with the vector previously obtained (pET14b with the cloned interferon- α 5 cDNA). The transformed bacteria are selected by their growth in LB medium with ampicillin, as the vector contains a gene which is resistant to this antibiotic.

25

Expression and purification of interferon- α 5:

[0026] The transformed bacteria are grown in LB medium with ampicillin at 37°C until an optical density of 0.4 at 600 nm is obtained. Then expression of the recombinant protein with IPTG is induced at a final concentration of 0.5 mM. In this way the *lac* promoter is induced and as a consequence the T7 RNA polymerase promoter which contains the vector and which regulates the expression of the cloned cDNA is induced. The culture is grown for a further 4 hours under the same conditions.

30

[0027] To obtain the extracts, once the bacteria have grown, centrifuging is carried out at 4°C. The precipitated bacteria are resuspended in 10 mM Tris/HCl buffer, 10% saccharose, 2 mM 2-mercaptoethanol and protease inhibitors. Homogenization was performed ultrasonically by incubation for 30 minutes with lysozyme at 4°C. This breaks down the bacterial wall and improves the yield of the extraction process. The cytosol extract is obtained by centrifuging the homogenate at 100,000 g for 90 minutes. Protein production is checked by analysing the cytosol fraction by SDS-PAGE.

35

[0028] His-interferon- α 5 merged protein is purified by chromatography of the cytosol extract in a 2 ml nickel column. The protein is eluted by washing the column with 1 M imidazole. The pure protein is processed with thrombin and the interferon- α 5 is subsequently repurified by molecular exclusion chromatography.

40

Expression and purification of human interferon- α 5 in *Solanum tuberosum*:

45 [0029] Construction of the expression vector and acquisition of transgenic plants.

[0030] The cDNA which codes for interferon- α 5 is cloned in an *Agrobacterium tumefaciens* expression vector. This vector contains the potato promoter (the most abundant protein in the *Solanum tuberosum* tubercle), as well as a sequence which codes for a series of histidine residues (1 kDa) and which are translated in phase with the cloned cDNA to yield a merged protein which contains a 1 kDa histidine tail at its terminal amine end followed by interferon- α 5, with a site between the two which can be cut by thrombin.

50

[0031] Once the expression vector has been obtained, competent bacteria of the GV2260 strain of *Agrobacterium tumefaciens* are prepared. The competent bacteria are transformed using the previously obtained vector. The transformed bacteria are selected by growth in LB medium with kanamycin, as the vector contains a gene which is resistant to that antibiotic.

55 [0032] Subsequently a coculture of the transformed bacteria with the plant material (*Solanum tuberosum* leaves cultivated *in vitro*) is performed and the plant cells resistant to kanamycin are selected. These cells are regenerated until transgenic plants are obtained.

Acquisition and purification of interferon- α 5:

[0033] Total protein extraction is performed from tubercles of the transgenic plants which express the interferon- α 5.

[0034] The purification of His-interferon- α 5 merged protein is carried out by chromatography of the protein extract obtained on a 2 ml nickel column. The protein is eluted by washing the column with 1 M imidazole. The pure protein is processed with thrombin and the interferon- α 5 is subsequently repurified using molecular exclusion chromatography.

IFN α subtypes in normal liver tissue and PBMC in healthy individuals

[0035] After extraction of the total RNA of the normal liver tissue samples the mRNA of the IFN α was amplified using universal primers for all the IFN α subtypes. The PCR amplification products were then cloned and sequenced. 41 clones from 4 different normal livers were analysed and we observed that the IFN α sequence in the 41 clones was the same and corresponded to the IFN α 5 subtype (Table 1). These results show that IFN α 5 is the only IFN α subtype expressed in normal liver. The partial cDNA sequence of the IFN α 5 obtained from all the clones was shown to be SEQ ID NO: 1.

[0036] To compare the profile of the IFN subtypes expressed in the liver with that expressed in PBMC the total RNA of the PBMC from 5 healthy controls was extracted and the IFN α mRNA was amplified with the universal primers for all the IFN α subtypes. Of the 43 clones analysed, 15 corresponded to the IFN α 5 subtype, 14 to the IFN α 1/13, 6 to the IFN α 21 and 8 clones to other IFN α subtypes (Table 1). These results indicate that the IFN α subtype profile expressed in PBMC differs from that expressed in normal liver.

IFN α subtypes in liver tissue and PBMC from patients with chronic hepatitis C

[0037] The above results show that the normal liver expresses IFN α 5, while PBMC express a variety of IFN α subtypes. In the liver parenchyma of patients with chronic hepatitis C there is mononuclear cell infiltrate, an important source of IFN α . This suggests that the profile of IFN α subtypes expressed by the liver in patients with chronic hepatitis C might differ from the profile found in normal liver. To investigate the expression of IFN α subtypes in chronic hepatitis C we extracted the total RNA from liver samples from 3 different patients and 2 PBMC samples. After amplifying the IFN α RNA with universal primers for all subtypes, we cloned and sequenced 24 clones of liver tissue and 18 clones of PBMC. As shown in Table 1, the PBMC from patients with chronic hepatitis C expressed IFN α 21, IFN α 5 and IFN α 7 (5, 12, and 1 clones respectively). In the liver tissue from these patients we found subtypes IFN α 21, IFN α 7 and IFN α 1/13 (8, 1 and 2 clones respectively) in addition to the IFN α 5 subtype (Table 1).

[0038] These data suggest that the production of IFN α by the mononuclear cell infiltrate can cause a change in the profile of IFN α subtypes expressed in the liver tissue of patients with chronic hepatitis C.

Levels of expression of IFN α mRNA in PBMC and the liver of patients with chronic hepatitis C and controls

[0039] Total RNA was extracted from PBMC and liver samples from patients with chronic hepatitis C (n=25 and 16, respectively), PBMC samples from healthy controls (n=20) and normal liver tissue samples obtained by laparotomy (n=12). The mRNA levels of IFN α were determined using the semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) technique using universal primers to amplify all the IFN α subtypes. The values are expressed as the ratio of IFN α mRNA to β -actin mRNA.

[0040] We found that the levels of expression of IFN α in the PMBC of patients with chronic hepatitis C were significantly increased in comparison with those found in healthy controls (3.2 ± 0.48 against 1.14 ± 0.26 ; $p=0.001$) (Figure 1A). This result was expected in a viral infection such as hepatitis C in which the PBMC are infected (14). On the other hand the levels of expression of IFN α mRNA were significantly reduced in the liver tissue from patients with chronic hepatitis C in comparison with that expressed in normal liver (0.12 ± 0.03 against 0.43 ± 0.12 ; $p=0.003$) (Figure 1B).

[0041] As observed previously, IFN α 5 is the only IFN α subtype detected in normal liver, while a mixture of subtypes is observed in the liver tissue of patients with chronic hepatitis C. Our findings indicate that in infection by HCV there is a marked reduction in the expression of the IFN α subtype normally expressed in liver tissue. Interestingly, IFN α mRNA levels in the livers of patients with chronic hepatitis C show a direct correlation with the Knodell index ($r=0.54$; $p<0.05$). This finding, together with the observation that the IFN α subtypes detected in the livers of patients with chronic hepatitis C are those observed in PBMC suggests that most of the IFN α mRNA found in the liver in hepatitis C comes from the inflammatory infiltrate. It appears possible that the reduction in the expression of liver IFN α (IFN α 5) may play a part in making the HCV infection chronic. As a result, these observations may have therapeutic implications if we also bear in mind the marked antiviral and antiproliferative activity of the IFN α 5 described by other authors (9).

Levels of expression of IFN mRNA in the PBMC and liver of patients with chronic hepatitis C and controls

[0042] IFN β , the second majority form of type 1 interferon, is a glycoprotein produced by a single gene. In viral infections transcription of the IFN α and IFN β genes is activated or repressed by various mechanisms (15). To analyse the expression of IFN β in chronic hepatitis C we determined IFN β mRNA levels in the same samples of liver tissue and PBMC previously used to determine the expression of IFN α .

[0043] As shown in Figure 2, we observed that IFN β mRNA levels (expressed as a ratio against β -actin) were significantly higher in both PBMC and the liver in patients with chronic hepatitis C in comparison with the PBMC findings in healthy controls and normal livers (1.66 ± 0.2 against 0.88 ± 0.16 ; $p=0.008$ in PBMC and 1.37 ± 0.23 against 0.97 ± 0.16 ; $p=0.011$ in liver). These results show that while HCV causes IFN α to be repressed in the liver, the expression of IFN β is increased in both the liver and PBMC. This indicates that HCV modulates the different type I IFN genes in the liver in a different way, and blocks the production of IFN α to permit the overexpression of IFN β .

Relationship between the expression of IFN α and IFN β genes with viral load, genotype and liver damage in chronic hepatitis C

[0044] In order to determine whether the expression of the IFN α or IFN β genes can be related to viral load or genotype we quantified the C virus RNA in the serum of all patients using the competitive PCR technique and determined the HCV genotype using a hybridization method with specific test materials. We found no correlation between the expression of the IFN α or IFN β genes (in the liver or PBMC) and C virus RNA levels in serum or the viral genotype.

Analysing the relationship between the expression of the type I IFN genes and the severity of liver damage in patients with chronic hepatitis C we found that IFN β mRNA levels in the liver correlated directly with serum aspartate aminotransferase values ($r=0.64$, $p=0.008$) and the Knodell index ($r=0.66$, $p=0.006$). Likewise the IFN α mRNA values in the liver showed a direct positive correlation with the Knodell index as mentioned previously.

Table 1.

IFN α subtypes in controls and patients with chronic hepatitis C.		
	Liver	PBMC
Control 1	9 IFNA5 clones	
Control 2	9 IFNA5 clones	
Control 3	11 IFNA5 clones	
Control 4	12 IFNA5 clones	
Control 5		3 IFNA5 clones 4 IFNA21 clones 2 IFNA1 clones
Control 6		8 IFNA5 clones
Control 7		10 IFNA1/13 clones 1 IFNA8 clone
Control 8		3 IFNA5 clones 2 IFNA21 clones 2 IFNA1/13 clones 1 IFNA22 clones
Control 9		2 IFNA10 clones 1 IFNA5 clone 1 IFNA2 clone 1 IFNA7 clone 1 IFNA8 clone 1 IFNA4 clone
RNA-HCV (+) 1	6 IFNA5 clones 2 IFNA21 clones 1 IFNA17 clone	7 IFNA5 clones 1 IFNA21 clone 1 IFNA7 clone

EP 1 077 068 B9 (W1B1)

Table 1. (continued)

IFN α subtypes in controls and patients with chronic hepatitis C.		
	Liver	PBMC
RNA-HCV (+) 2	2 IFNA5 clones 4 IFNA21 clones	5 IFNA5 clones 4 IFNA21 clones
RNA-HCV (+) 3	5 IFNA5 clones 2 IFNA21 clones 2 IFNA1 clones	

Description of the figures

[0045] Figure 1: Expression of alpha interferon/ β -actin mRNA (ordinate) in peripheral blood mononuclear cells (A) and in the liver (B) of healthy controls and patients with chronic hepatitis C (HCV-RNA+) (abscissa).

[0046] Figure 2: Expression of beta interferon/ β -actin mRNA (ordinate) in peripheral blood mononuclear cells (A) and in the liver (B) of healthy controls (C) and patients with chronic hepatitis C (HCV-RNA+) (abscissa).

[0047] Figure 3: Relationship between the initial quantity of total RNA (abscissa) and the strength of the PCR product band obtained by amplifying the mRNA of IFN α (\circ), IFN β (\blacktriangle) and β -actin (\blacklozenge) (ordinate, as counts x mm²) in PBMC (A) and liver (B) samples.

LIST OF SEQUENCES

GENERAL INFORMATION:

APPLICANT:

[0048] NAME: INSTITUTO CIENTIFICO Y TECNOLOGICO DE NAVARRA, S.A.

STREET: Avenida Pío XII, 53
TOWN: Pamplona
STATE OR PROVINCE: Navarra
COUNTRY: Spain
POST CODE: 31008
TELEPHONE: 948-10 56 00
FAX: 948-17 52 23

TITLE: "USE OF ALPHA 5 INTERFERON IN THE TREATMENT OF VIRAL LIVER DISEASES".

NUMBER OF SEQUENCES: 1

ADDRESS FOR CORRESPONDENCE:

[0049] NAME: INSTITUTO CIENTIFICO Y TECNOLOGICO DE NAVARRA, S.A.

STREET: Avenida Pío XII, 53
TOWN: Pamplona
STATE OR PROVINCE: Navarra
COUNTRY: Spain
POST CODE: 31008

COMPUTER READABLE FORM:

[0050] TYPE OF MEDIUM: 3.5" DISK
COMPUTER: PC
OPERATING SYSTEM: WINDOWS
WORD PROCESSOR: WORD

INFORMATION ON THE LAWYER/AGENT:

5 [0051] NAME: ALBERTO DE ELZABURU
REGISTER NUMBER: 232/1
REFERENCE/REGISTER NUMBER: P-99043

TELECOMMUNICATIONS INFORMATION:

10 [0052] TELEPHONE: 91 7009400
FAX: 91 3193810
TELEX OR ELECTRONIC MAIL: elzaburu@elzaburu.es

INFORMATION FOR SEQ ID NO.: 1

15 [0053] CHARACTERISTICS OF THE SEQUENCE:

LENGTH: 274 base pairs

TYPE: nucleotides

NUMBER OF STRANDS: 1

CONFIGURATION: linear

20 TYPE OF MOLECULE: cDNA

HYPOTHETICAL: NO

ANTI-DIRECTION: NO

SOURCE OF ORIGIN:

Organism: Homo Sapiens

25 Type of tissue: liver

POSITION IN THE GENOME: Chromosome 9

CHARACTERISTIC:

NAME/KEY: IFN α 5

Method of identification: RT-PCR, Sequencing

30 OTHER INFORMATION:

Nucleotides 672 to 945 in the sequence of the IFN α 5 gene published in the Genbank database under access number X02956.

35

40

45

50

55

EP 1 077 068 B9 (W1B1)

DESCRIPTION OF THE SEQUENCE SEQ ID NO: 1

[0054]

5	TC CAT GAG ATG ATC CAG CAG ACC TTC AAT CTC TTC AGC ACA AAG GAC TCA	50
	His Glu Met Ile Gln Gln Thr Phe Asn Leu Phe Ser Thr Lys Asp Ser	
	1 5 10 15	
10	TCT GCT ACT TGG GAT GAG ACA CTT CTA GAC AAA TTC TAC ACT GAA CTT TAC	101
	Ser Ala Thr Trp Asp Glu Thr Leu Leu Asp Lys Phe Tyr Thr Glu Leu Tyr	
	20 25 30	
15	CAG CAG CTG AAT GAC CTG GAA GCC TGT ATG ATG CAG GAG GTT GGA GTG GAA	152
	Gln Gln Leu Asn Asp Leu Glu Ala Cys Met Met Gln Glu Val Gly Val Glu	
	35 40 45 50	
20	GAC ACT CCT CTG ATG AAT GTG GAC TCT ATC CTG ACT GTG AGA AAA TAC TTT	203
	Asp Thr Pro Leu Met Asn Val Asp Ser Ile Leu Thr Val Arg Lys Tyr Phe	
	55 60 65	
25	CAA AGA ATC ACC CTC TAT CTG ACA GAG AAG AAA TAC AGC CCT TGT GCA TGG	254
	Gln Arg Ile Thr Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp	
	70 75 80	
30	GAG GTT GTC AGA GCA GAA AT	274
	Glu Val Val Arg Ala Glu	
	85 90	

Claims

- 35 1. Use of IFN-alpha 5 or the gene sequence coding for IFN-alpha 5 in the production of compositions useful for treatment of liver diseases.
2. Use according to claim 1 wherein those compositions are useful against chronic hepatitis C.
- 40 3. Use according to claim 1 wherein those compositions are useful against cirrhosis of viral origin.
4. Use according to claim 1 wherein those compositions are useful against hepatocellular carcinoma.
- 45 5. Use according to anyone of claims 1-4, in which the composition comprises an IFN-alpha 5 recombinant protein obtained by cloning in a suitable host an expression vector comprising the gene sequence coding for IFN-alpha 5.
6. Use according to claim 5, in which the cloned host is a eucaryote organism, preferably *Escherichia coli*.
7. Use according to claim 5, in which the cloned host is a procaryote organism, preferably *Solanum tuberosum*.
- 50 8. Use according to claims 1-7 in which the composition can be included in any foodstuff.
- 55 9. Use according to claims 1 to 4, **characterised by** those compositions comprising the gene sequence coding for IFN-alpha 5 and being applied by somatic gene therapy.

Patentansprüche

1. Verwendung von IFN-Alpha 5 oder der für IFN-Alpha 5 kodierenden Gensequenz in der Herstellung von Zusammensetzungen, die für Behandlungen von Lebererkrankungen nützlich sind.
2. Verwendung nach Anspruch 1, in der diese Zusammensetzungen gegen chronische Hepatitis C nützlich sind.
3. Verwendung nach Anspruch 1, in der diese Zusammensetzungen gegen Zirrrose virischen Ursprungs nützlich sind.
4. Verwendung nach Anspruch 1, in der diese Zusammensetzungen gegen das hepatozelluläres Karzinom nützlich sind.
5. Verwendung nach einem der Ansprüche 1 bis 4, in der die Zusammensetzung ein IFN-Alpha 5 rekombiniertes Protein beinhaltet, das durch Klonation eines Expressionsvektors in einem passenden Wirt erhalten wird, der die für IFN-Alpha 5 kodierende Gensequenz beinhaltet.
6. Verwendung nach Anspruch 5, in der der geklonte Wirt ein eucaryotischer Organismus ist, vorzugsweise *Escherichia coli*.
7. Verwendung nach Anspruch 5, in der der geklonte Wirt ein procaryotischer Organismus ist, vorzugsweise *Solanum tuberosum*.
8. Verwendung nach Ansprüchen 1 bis 7, in der die Zusammensetzung in jedes Nahrungsmittel eingeschlossen werden kann.
9. Verwendung nach Ansprüchen 1 bis 4, **dadurch gekennzeichnet, daß** diese Zusammensetzungen die für IFN-Alpha 5 kodierende Gensequenz beinhalten und bei der somatischen Gentherapie angewendet werden.

Revendications

1. Utilisation de l'IFN-alpha 5 ou de la séquence génétique codant pour l'IFN-alpha 5 dans la production de compositions utiles pour le traitement des maladies hépatiques.
2. Utilisation selon la revendication 1, dans laquelle ces compositions sont utiles pour lutter contre l'hépatite C chronique.
3. Utilisation selon la revendication 1, dans laquelle ces compositions sont utiles pour lutter contre la cirrhose d'origine virale.
4. Utilisation selon la revendication 1, dans laquelle ces compositions sont utiles pour lutter contre le carcinome hépato-cellulaire.
5. Utilisation selon l'une quelconque des revendications 1-4, dans laquelle la composition comprend une protéine recombinante IFN-alpha 5 obtenue au moyen du clonage dans un hôte approprié d'un vecteur d'expression comprenant la séquence génétique codant pour l'IFN-alpha 5.
6. Utilisation selon la revendication 5, dans laquelle l'hôte cloné est un organisme eucaryote, de préférence *Escherichia coli*.
7. Utilisation selon la revendication 5, dans laquelle l'hôte cloné est un organisme procaryote, de préférence *Solanum tuberosum*.
8. Utilisation selon les revendications 1-7, dans laquelle la composition peut être incluse dans tout produit alimentaire.
9. Utilisation selon les revendications 1 à 4, **caractérisée en ce que** ces compositions comprennent la séquence génétique codant pour l'IFN-alfa 5 et sont appliquées au moyen de thérapie génétique somatique.




Figure 1




Figure 2




Figure 3